Tom Shimabukuro

Dr. Tom Shimabukuro is the deputy director of the Immunization Safety Office at the US Centers for Disease Control and Prevention (CDC). The Immunization Safety Office conducts post-licensure safety monitoring of US vaccines.

Dr. Shimabukuro has also served as the Vaccine Adverse Event Reporting System (VAERS) team lead and acting team lead of the Vaccine Safety Datalink (VSD) team in the Immunization Safety Office. Prior to coming to the Immunization Safety Office, Dr. Shimabukuro coordinated pandemic influenza planning for CDC’s Immunization Services Division.

He received his medical degree from New York University. He did his internship at Emory University and preventive medicine residency at the Johns Hopkins University. Dr. Shimabukuro also completed a fellowship as an Epidemic Intelligence Service Officer at CDC. He is board certified in public health and general preventive medicine. ¹⁾

Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring

Winston E Abara, Julianne Gee, Mark Delorey, Ye Tun, Yi Mu, David K Shay, and Tom Shimabukuro

Author information Article notes Copyright and License information Disclaimer CDC COVID-19 Response Team, Centers for Disease Control and Prevention Atlanta, Georgia United States Corresponding author: Winston Abara; moc.oohay@araba_notsniW Alternate author: Julianne Gee; vog.cdc@2gzd; 404-639-1885

Abstract Using meta-analytic methods, we calculated expected rates of 21 potential adverse events of special interest (AESI) that would occur following COVID-19 vaccination within 1-, 7-, and 42-day intervals without causal associations. Based on these expected rates, if 10,000,000 persons are vaccinated, 0.5, 3.7, and 22.5 Guillain-Barre syndrome cases; 0.3, 2.4, and 14.3 myopericarditis cases; and 236.5, 1655.5, and 9932.8 all-cause deaths would occur coincidentally within 1, 7, and 42 days post-vaccination, respectively. Expected rates of potential AESI can contextualize events associated temporally with immunization, aid in safety signal detection, guide COVID-19 vaccine health communications, and inform COVID-19 vaccine benefit-risk assessments. ²⁾

News Release 3-Sep-2021 No serious health effects linked to mRNA COVID-19 vaccines

Study of 6.2 million patients by Kaiser Permanente and CDC researchers will continue for 2 years. Peer-Reviewed Publication

The study published September 2 in JAMA reports the first comprehensive findings of the Vaccine Safety Datalink (VSD), which studies patient records for 12 million people in 5 Kaiser Permanente service regions along with HealthPartners in Minneapolis, the Marshfield Clinic in Wisconsin, and Denver Health. The work is supported by the Centers for Disease Control and Prevention (CDC).

“These results from our safety surveillance are reassuring,” said lead author Nicola Klein, MD, PhD, director of the Kaiser Permanente Vaccine Study Center and principal investigator of the Vaccine Safety Datalink’s COVID-19 rapid cycle analysis.

“The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. The Vaccine Safety Datalink is ideally suited to carry out this important surveillance and we will continue to monitor the safety of all vaccines that protect against COVID-19,” added Dr. Klein, who is also a senior research scientist with the Kaiser Permanente Division of Research.

The study reported findings from mid-December 2020 through June 26, 2021. Some of the early findings had been summarized previously and reported at public meetings of the CDC’s Advisory Committee on Immunization Practices, though the JAMA article is the VSD’s first comprehensive report of its safety surveillance of the Pfizer and Moderna mRNA vaccines.

“The results of this study are a great example of how seriously CDC takes vaccine safety, and how thorough and transparent we are in our safety monitoring efforts,” said Tom Shimabukuro, MD, leading vaccine safety for the COVID-19 response and the deputy director of CDC’s Immunization Safety Office. “It is our top priority to do the science and communicate quickly and clearly with healthcare providers and the public, as COVID-19 vaccines continue to undergo the most intensive safety monitoring in U.S. history. Getting vaccinated remains the best way to protect yourself and your loved ones against a virus that has taken millions of lives.”

The VSD’s rapid-cycle analysis for the mRNA COVID-19 vaccines will continue tracking newly vaccinated patients for at least 2 years. The VSD, established in 1990 and led by the CDC, Kaiser Permanente, and other health care systems, is the nation’s premier active surveillance system for vaccine safety. ³⁾

Release the V-safe pregnancy data - now Over one year on, we still have not seen this data. Is this the FDA's biggest scandal since DES? Substack - Arkmedic's blog by Dr Ah Kahn Syed -October 15, 2022

The CDC rushed out two papers in 2021 to show how safe the COVID vaccines were by reporting on the 5,104 women who had registered for follow-up after their jab. The second of those reports did not report on pregnancies beyond 20 weeks.

This means that… Despite the CDC publishing within weeks of what appeared to be favourable pregnancy data from the v-safe pregnancy registry they have NEVER published any data for the full-term pregnancy outcomes of the 5,104 women registered in their follow-up study even though they have all that data and have had it for at minimum of 3 months.

The lead author on the original study is Tom Shimabukuro who has almost no image trace on the internet. Tom likes to stay hidden his contacts like to push our favourite Victoria Male into the limelight to defend the indefensible…

Interestingly, Viki has another friend on her twitter feed (apart from Teresa Kelly who we have discussed previously) and who is a bona fide mutton crew member - Kevin Ault. Kevin Ault is a member of ACIP (the CDC Advisory Committee on Vaccine Practices) and therefore has an undeclared conflict of interest in publicly pushing COVID vaccinations in pregnancy. ⁴⁾